Drugs / TC-N201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-05 | TCRCure Biopharma Ltd. | Regulatory “TC-N201注射液”临床试验申请获得受理 tcrcure.com ↗
9 月 3 日据 CDE 官网显示，“ TC-N201 注射液”临床试验申请获得受理。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-05 | TCRCure Biopharma Ltd. | “TC-N201注射液”临床试验申请获得受理 tcrcure.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-N201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07307053 ↗ |
| Modality | Cell therapy | “genetically engineered TCR-T cell product” NCT07307053 ↗ |